84 research outputs found
MARKET TIMING ABILITIES OF LARGE-CAP EQUITY MUTUAL FUND MANAGERS: EVIDENCE FROM INDIA
This study investigates the Market Timing Ability (MTA) of large-cap equity fund managers in India. The extensions of Treynor and Mazuy (TM) model and Henriksson and Merton (HM) model have been used by adding six additional factors related to the public information, 91-days Treasury billâs yield, the dividend yield on CNX 500 index, term structure of interest rates, the price-to-earnings ratio, yield from foreign exchange rates changes, and growth rate in gold prices. The extended models are termed, conditional models. This study has used time-series data of large-cap equity funds. The results of the conditional and unconditional versions of TM and HM models reveal that the large-cap equity funds as a whole do not possess significant MTA, even though a considerable percentage of the funds under each of the models show significant positive MTA. The study also highlights that the inclusion of the public information variables reconstitutes the impact of the market timing factor and other beta estimates in the model
Some fixed point theorems on non-convex sets
[EN] In this paper, we prove that ifKis a nonempty weakly compact setin a Banach spaceX,T:KâKis a nonexpansive map satisfyingx+Tx2âKfor allxâKand ifXis3âuniformly convex orXhas theOpial property, thenThas a fixed point in KRadhakrishnan, M.; Rajesh, S.; Agrawal, S. (2017). Some fixed point theorems on non-convex sets. Applied General Topology. 18(2):377-390. doi:10.4995/agt.2017.7452SWORD37739018
Multi Response Optimization of process parameters of friction stir welded AA6061 T6 and AA 7075 T651 Using Response Surface Methodology
232-234In this work friction stir welding of AAA 6061 T6 with 7075-T651 of 6mm thickness was carried out. A 31 run Central composite design was adopted to run the experiments. The process parameter ranges were identified based on trial runs. The optimization of the process parameters was done based on the results and plots obtained from Design Expert 10.0 software and the mathematical model was developed for the same. The microhardness tests were also studied. The advancing side was 6061 T6 due to its formability properties. Interference of each process parameters on the Tensile strength was obtained from the contour plots. The fitness was justified by Anova
Multi Response Optimization of process parameters of friction stir welded AA6061 T6 and AA 7075 T651 Using Response Surface Methodology
In this work friction stir welding of AAA 6061 T6 with 7075-T651 of 6mm thickness was carried out. A 31 run Central composite design was adopted to run the experiments. The process parameter ranges were identified based on trial runs. The optimization of the process parameters was done based on the results and plots obtained from Design Expert 10.0 software and the mathematical model was developed for the same. The microhardness tests were also studied. The advancing side was 6061 T6 due to its formability properties. Interference of each process parameters on the Tensile strength was obtained from the contour plots. The fitness was justified by Anova
Development and Adoption of Bt Cotton in India : Economic, Environmental and Health Issues
Bt Cotton, is genetically engineered with Bt (Bacillus thuringiensis), a bio-toxin which comes from soil bacterium. Bt which was isolated from soil in 1911, has been available to farmers as an organic pesticide since 1930..The engineered Bt gene produces a protein that cuts into the guts of specific insects, rendering the cotton resistant to these insects. Biotechnology for control of bollworms is made available in the seed itself. Farmers have to just sow the Bt cotton seeds as they do with conventional seeds. The resulting plants have the in-built ability to produce Bt protein within their body and defend themselves from bollworms. No extra efforts or equipment are needed to utilize this technology. But after the introduction of Bt cotton it brought into focus a variety of issues like economic, environmental and health and it has a controversy against to adopt it. Hence, the present study focused on the above issues
Development and Adoption of Bt Cotton in India : Economic, Environmental and Health Issues
Bt Cotton, is genetically engineered with Bt (Bacillus thuringiensis), a bio-toxin which comes from soil bacterium. Bt which was isolated from soil in 1911, has been available to farmers as an organic pesticide since 1930..The engineered Bt gene produces a protein that cuts into the guts of specific insects, rendering the cotton resistant to these insects. Biotechnology for control of bollworms is made available in the seed itself. Farmers have to just sow the Bt cotton seeds as they do with conventional seeds. The resulting plants have the in-built ability to produce Bt protein within their body and defend themselves from bollworms. No extra efforts or equipment are needed to utilize this technology. But after the introduction of Bt cotton it brought into focus a variety of issues like economic, environmental and health and it has a controversy against to adopt it. Hence, the present study focused on the above issues
Development and Adoption of Bt Cotton in India : Economic, Environmental and Health Issues
Bt Cotton, is genetically engineered with Bt (Bacillus thuringiensis), a bio-toxin which comes from soil bacterium. Bt which was isolated from soil in 1911, has been available to farmers as an organic pesticide since 1930..The engineered Bt gene produces a protein that cuts into the guts of specific insects, rendering the cotton resistant to these insects. Biotechnology for control of bollworms is made available in the seed itself. Farmers have to just sow the Bt cotton seeds as they do with conventional seeds. The resulting plants have the in-built ability to produce Bt protein within their body and defend themselves from bollworms. No extra efforts or equipment are needed to utilize this technology. But after the introduction of Bt cotton it brought into focus a variety of issues like economic, environmental and health and it has a controversy against to adopt it. Hence, the present study focused on the above issues
Cytoskeletal vimentin regulates cell size and autophagy through mTORC1 signaling
The nutrient-activated mTORC1 (mechanistic target of rapamycin kinase complex 1) signaling pathway determines cell size by controlling mRNA translation, ribosome biogenesis, protein synthesis, and autophagy. Here, we show that vimentin, a cytoskeletal intermediate
filament protein that we have known to be important for wound healing and cancer progression, determines cell size through mTORC1 signaling, an effect that is also manifested at
the organism level in mice. This vimentin-mediated regulation is manifested at all levels of
mTOR downstream target activation and protein synthesis. We found that vimentin maintains normal cell size by supporting mTORC1 translocation and activation by regulating the
activity of amino acid sensing Rag GTPase. We also show that vimentin inhibits the autophagic flux in the absence of growth factors and/or critical nutrients, demonstrating growth
factor-independent inhibition of autophagy at the level of mTORC1. Our findings establish
that vimentin couples cell size and autophagy through modulating Rag GTPase activity of
the mTORC1 signaling pathway
Identification of novel therapeutics for complex diseases from genome-wide association data
Background: Human genome sequencing has enabled the association of phenotypes with genetic loci, but our ability to effectively translate this data to the clinic has not kept pace. Over the past 60 years, pharmaceutical companies have successfully demonstrated the safety and efficacy of over 1,200 novel therapeutic drugs via costly clinical studies. While this process must continue, better use can be made of the existing valuable data. In silico tools such as candidate gene prediction systems allow rapid identification of disease genes by identifying the most probable candidate genes linked to genetic markers of the disease or phenotype under investigation. Integration of drug-target data with candidate gene prediction systems can identify novel phenotypes which may benefit from current therapeutics. Such a drug repositioning tool can save valuable time and money spent on preclinical studies and phase I clinical trials. Methods. We previously used Gentrepid (http://www.gentrepid.org) as a platform to predict 1,497 candidate genes for the seven complex diseases considered in the Wellcome Trust Case-Control Consortium genome-wide association study; namely Type 2 Diabetes, Bipolar Disorder, Crohn's Disease, Hypertension, Type 1 Diabetes, Coronary Artery Disease and Rheumatoid Arthritis. Here, we adopted a simple approach to integrate drug data from three publicly available drug databases: the Therapeutic Target Database, the Pharmacogenomics Knowledgebase and DrugBank; with candidate gene predictions from Gentrepid at the systems level. Results: Using the publicly available drug databases as sources of drug-target association data, we identified a total of 428 candidate genes as novel therapeutic targets for the seven phenotypes of interest, and 2,130 drugs feasible for repositioning against the predicted novel targets. Conclusions: By integrating genetic, bioinformatic and drug data, we have demonstrated that currently available drugs may be repositioned as novel therapeutics for the seven diseases studied here, quickly taking advantage of prior work in pharmaceutics to translate ground-breaking results in genetics to clinical treatments. © 2014 Grover et al.; licensee BioMed Central Ltd
- âŠ